CFO of Array BioPharma Inc. (ARRY, Financial) Michael Carruthers sells 2,045 shares of ARRY on 11/23/2009 at an average price of $2.01 a share.
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases. The company's proprietary drug development pipeline is focused on the treatment of cancer and inflammatory disease and includes clinical candidates that are designed to regulate therapeutically important targets. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas. Array Biopharma Inc. has a market cap of $92.9 million; its shares were traded at around $1.93 with and P/S ratio of 3.7. Array Biopharma Inc. had an annual average earning growth of 32.7% over the past 5 years.
ARRY is in the portfolios of Jean-Marie Eveillard of Arnhold & S. Bleichroeder Advisers, LLC.
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases. The company's proprietary drug development pipeline is focused on the treatment of cancer and inflammatory disease and includes clinical candidates that are designed to regulate therapeutically important targets. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas. Array Biopharma Inc. has a market cap of $92.9 million; its shares were traded at around $1.93 with and P/S ratio of 3.7. Array Biopharma Inc. had an annual average earning growth of 32.7% over the past 5 years.
ARRY is in the portfolios of Jean-Marie Eveillard of Arnhold & S. Bleichroeder Advisers, LLC.
Insiders' Positions with ARRY
- Sell:: CFO Michael Carruthers sold 2,049 shares of ARRY stock on 10/23/2009 at the average price of 2.01, the price of the stock has decreased by 3.98% since
- Sell:: CFO Michael Carruthers sold 1,315 shares of ARRY stock on 09/25/2009 at the average price of 2.77, the price of the stock has decreased by 30.32% since
- Sell:: CFO Michael Carruthers sold 882 shares of ARRY stock on 08/24/2009 at the average price of 4.17, the price of the stock has decreased by 53.72% since
- Sell:: CFO Michael Carruthers sold 925 shares of ARRY stock on 07/30/2009 at the average price of 3.95, the price of the stock has decreased by 51.14% since
- Sell:: CFO Michael Carruthers sold 1,170 shares of ARRY stock on 06/22/2009 at the average price of 3.06, the price of the stock has decreased by 36.93% since
